Waldenstrom Macroglobulinemia × Dexamethasone × Clear all Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Phase 2 Completed
25 enrolled
VIWA-1
Phase 2 Recruiting
80 enrolled
Loncastuximab Tesirine in WM
Phase 2 Recruiting
36 enrolled
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Phase 3 Completed
202 enrolled
RAINBOW
Phase 2/3 Recruiting
148 enrolled
Ballondor
Phase 2 Recruiting
54 enrolled
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Phase 2 Completed
50 enrolled 11 charts
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Phase 2 Completed
7 enrolled 10 charts
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Phase 1/2 Completed
9 enrolled 8 charts
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
Phase 2 Completed
59 enrolled
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Phase 2 Completed
26 enrolled 14 charts
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 2 Completed
35 enrolled
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Phase 2 Completed
21 enrolled 10 charts
CaRD
Phase 2 Completed
31 enrolled 10 charts
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Phase 1 Completed
25 enrolled
BOMB-THROW
Phase 2 Unknown
15 enrolled
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Phase 2 Completed
43 enrolled 5 charts
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
Phase 2 Completed
32 enrolled 7 charts
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Phase 1 Completed
48 enrolled 26 charts
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
Phase 2 Completed
36 enrolled 7 charts
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Phase 1 Terminated
7 enrolled 8 charts
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
Phase 2 Completed
23 enrolled 9 charts
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Phase 2 Withdrawn
S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia
Phase 2 Completed
9 enrolled
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
Phase 2 Withdrawn
BDR-WM
Phase 2 Completed
59 enrolled